Why Medicare Drug Negotiations Are Now a Long-Term Industry Reality

The US Supreme Court on Monday declined to hear a series of appeals from pharmaceutical companies challenging the federal government’s authority to negotiate Medicare drug prices. The decision leaves in place rulings from lower courts that dismissed the manufacturers' claims, effectively allowing the program to continue without further judicial intervention for the time being.¹

By declining the cases without comment, the justices have maintained the status quo for the Inflation Reduction Act of 2022. This legislation established the first-ever framework for the federal government to haggle directly with drugmakers over the costs of high-expenditure medications within the Medicare program.²

What Did Pharma Argue Against the Medicare Negotiations?

The legal framework and industry challenges the appeals brought before the court represented a broad effort by industry leaders, including AstraZeneca and Janssen, to halt the program. The companies argued that the negotiation process was "sham negotiation" that violated several constitutional protections.³ Specifically, manufacturers claimed the program violated the Fifth Amendment by taking property without just compensation and the First Amendment by compelling them to adopt the government's characterization of the prices as "fair."³ However, lower courts consistently rejected these arguments, a position the Supreme Court has now left undisturbed.

Because companies have the option to withdraw from the Medicare and Medicaid markets—though they are essential to commercial success—the courts have ruled that the government can set pricing terms as a condition of participation.³ Furthermore, the industry arrived at the Supreme Court at a disadvantage because no lower courts had ruled in their favor, meaning there was no circuit split to resolve.

Why Does this Matter for Pharma?

This development signals that the Medicare Drug Price Negotiation Program is no longer a temporary legislative hurdle but an established regulatory reality. The importance of this ruling lies in its impact on long-term commercial strategy and life-cycle management.

1. Integration into commercial planning: The program is already actively affecting the market. The first round of negotiations, which took effect in January, involved 10 high-expenditure drugs, such as the blood thinner Eliquis and the diabetes treatment Farxiga. AstraZeneca reported to the Court that this process resulted in a 68% discount off the list price for Farxiga.³ With the legal path cleared, companies must now incorporate these steep, government-mandated discounts into their revenue forecasts much earlier in a drug's life cycle.

2. Expansion into high-growth classes: The scope of the program is rapidly increasing. The government has already negotiated prices for 25 drugs, including some popular GLP-1s used for weight loss and diabetes like Ozempic, Rybelsus, and Wegovy.² A third round of negotiations is currently underway, which could bring the total number of affected drugs to 40.² This expansion into high-growth therapeutic areas means that few sectors of the industry will remain untouched by the program’s reach.

3. Legislative permanence and political reality: The ruling emphasizes that internal program changes or political shifts may be the only remaining avenues for industry relief. The statute does not include an end date, and with the Supreme Court declining to intervene, stopping the program could require an act of Congress.² Despite the fact that the IRA passed without Republican support and has faced criticism from current and former administrations, the executive branch has fully embraced the authority to bring drugmakers to the negotiating table.²

What Is the Financial and Market Outlook?

The financial stakes for the federal government and the industry are significant. The first round of negotiations is expected to save the government $6 billion, while the second round is projected to save an additional $12 billion.³ While drugmakers continue to argue that these price controls will negatively impact future innovation and have called for a greater focus on pharmacy benefit managers, the judicial system has, for now, provided a clear answer.² The Supreme Court's refusal to hear these appeals could mark the end of the initial legal resistance phase and the beginning of a new era of federal drug price transparency in the United States.

References

• Reuters. US Supreme Court rebuffs pharma challenge to Biden-era drug price. Reuters. Published May 18, 2026. Accessed May 18, 2026. https://www.reuters.com/world/us-supreme-court-rebuffs-pharma-challenge-biden-era-drug-price-2026-05-18/
• Mark Sherman, Amanda Swenson. Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations. AP News. Published May 18, 2026. Accessed May 18, 2026. https://apnews.com/article/supreme-court-medicare-prescription-drug-price-negotiation-1b67dff5ab8c13865e2b33860b0978ce
• John Fritze, Tami Luhby. Supreme Court rejects Big Pharma appeals challenging negotiated drug prices in Medicare. CNN. Published May 18, 2026. Accessed May 18, 2026. https://www.cnn.com/2026/05/18/politics/drug-prices-supreme-court-medicare